Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

William Nixon

Family Medicine Guntersville, AL Medical Doctor

NPI 1699731927 CMS profile 349380

2337 Homer Clayton Drive, Guntersville, AL 35976

Open in the dashboard

General payments

$8,126

518 records reported · program years 2019–2025

Research payments

$7,564

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$7,139,175 paid to institutions, not to them · program years 2019–2025

Through program year 2025, William Nixon of Guntersville, AL is reported in the CMS Open Payments database as having received $8,126 across 518 general payments and $7,564 in research payments paid to them. Separately, studies naming them as principal investigator received $7,139,175 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,308 69
2024 General $1,042 66
2023 General $1,587 93
2022 General $1,308 90
2021 General $1,154 79
2021 Research $564 1
2020 General $659 43
2020 Research $7,000 1
2019 General $1,067 78

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Nixon
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to William Nixon were reported at $1,308. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year William Nixon Family Medicine median Middle half National median
2019 $1,067 $150 $41–$543 $163
2020 $659 $120 $32–$415 $114
2021 $1,154 $137 $35–$551 $132
2022 $1,308 $137 $37–$512 $149
2023 $1,587 $149 $42–$545 $160
2024 $1,042 $156 $44–$560 $164
2025 $1,308 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,425 105 payments
  2. Pfizer Inc. $859 61 payments
  3. GlaxoSmithKline, LLC. $499 31 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $483 32 payments
  5. Amgen Inc. $335 22 payments
  6. Otsuka America Pharmaceutical, Inc. $326 15 payments
  7. Merck Sharp & Dohme Corporation $268 17 payments
  8. AstraZeneca Pharmaceuticals LP $238 15 payments
  9. Novartis Pharmaceuticals Corporation $237 9 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $235 14 payments
  11. Other $3,221 197 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,126 518 payments
Products named General payments · program years 2019–2025
  1. ELIQUIS $478 33 payments
  2. VRAYLAR $472 32 payments
  3. TRELEGY ELLIPTA $386 24 payments
  4. QULIPTA $369 33 payments
  5. NURTEC ODT $347 24 payments
  6. XIFAXAN $328 21 payments
  7. REXULTI $326 15 payments
  8. UBRELVY $320 27 payments
  9. Repatha $289 19 payments
  10. ENTRESTO $237 9 payments
  11. Other $7,681 471 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $7,564 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 141 drugs

Part D claims

7,920

Median for Family Practice: 1,826

Drug cost

$593,317

Median for Family Practice: $120,094

Branded share of claims

23.3%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 121 $139,868
Eliquis Apixaban Brand 135 $93,173
Januvia Sitagliptin Phosphate Brand 50 $34,335
Daptomycin Generic 29 $33,950
Jardiance Empagliflozin Brand 20 $26,209
Ozempic Semaglutide Brand 18 $21,391
Tresiba Flextouch U-200 Insulin Degludec Brand 20 $16,851
Synjardy Empagliflozin/Metformin Hcl Brand 12 $15,218
Entresto Sacubitril/Valsartan Brand 14 $14,580
Spiriva Respimat Tiotropium Bromide Brand 19 $13,092

The 10 drugs with the highest cost, of 141 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 121 billing codes

Paid by Medicare

$109,265

Of which drugs: $2,197

Medicare patients

455

Average age 76

Services billed

11,784

255 women, 200 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Ischemic heart disease 33%
Diabetes 32%
Atrial fibrillation 26%
COPD 19%
Depression 19%
Chronic kidney disease 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 67 5,442 $502
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 38 77 $379
Injection, methylprednisolone acetate, 80 mg J1040 Office 30 31 $100
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 111 1,024 $71
Injection, ceftriaxone sodium, per 250 mg J0696 Office 23 96 $31
Injection, ketorolac tromethamine, per 15 mg J1885 Office 24 56 $25

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 31 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
$86 — —
NURTEC ODT
$71 — —
TRELEGY ELLIPTA
$67 — —
ZAVZPRET
$55 — —
REXULTI
$53 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 31 with Patron

Records

520 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record